AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
Amgen (NASDAQ: AMGN) has announced its participation in the 35th Annual Oppenheimer Healthcare Life Sciences Conference scheduled for Wednesday, February 12, 2025, at 11:20 a.m. ET. Narimon Honarpour, senior vice president of global development at Amgen, will represent the company at the conference.
The presentation will be accessible through a live webcast simultaneously available to investors, news media, and the general public. The webcast can be accessed through Amgen's website (www.amgen.com) under the Investors section, along with other management presentations from investor and medical conferences. The presentation will remain archived and available for replay on the website for a minimum of 90 days following the event.
Amgen (NASDAQ: AMGN) ha annunciato la sua partecipazione alla 35ª Conferenza Annuale Oppenheimer sulle Scienze della Vita e della Salute, in programma per mercoledì 12 febbraio 2025, alle 11:20 ET. Narimon Honarpour, vicepresidente senior dello sviluppo globale di Amgen, rappresenterà l'azienda alla conferenza.
La presentazione sarà accessibile tramite un webcast in diretta, simultaneamente disponibile a investitori, media e pubblico generale. Il webcast può essere raggiunto attraverso il sito web di Amgen (www.amgen.com) nella sezione Investitori, insieme ad altre presentazioni della gestione da conferenze per investitori e medici. La presentazione rimarrà archiviata e disponibile per la visione on demand sul sito per un minimo di 90 giorni dopo l'evento.
Amgen (NASDAQ: AMGN) ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer, programada para el miércoles 12 de febrero de 2025, a las 11:20 a.m. ET. Narimon Honarpour, vicepresidente senior de desarrollo global en Amgen, representará a la empresa en la conferencia.
La presentación estará accesible a través de un webcast en vivo, disponible simultáneamente para inversores, medios de comunicación y el público en general. El webcast se puede acceder a través del sitio web de Amgen (www.amgen.com) en la sección de Inversores, junto con otras presentaciones de la dirección de conferencias para inversores y médicos. La presentación permanecerá archivada y estará disponible para su reproducción en el sitio web por un mínimo de 90 días después del evento.
암젠 (NASDAQ: AMGN)은 2025년 2월 12일 수요일 오전 11시 20분 ET에 예정된 제35회 오펜하이머 헬스케어 생명과학 컨퍼런스에 참여한다고 발표했습니다. 나리몬 호나르푸르 암젠의 글로벌 개발 부사장이 회의에서 회사를 대표할 것입니다.
발표는 투자자, 언론 및 일반 대중이 동시에 이용할 수 있는 실시간 웹캐스트를 통해 접근할 수 있습니다. 웹캐스트는 암젠의 웹사이트 (www.amgen.com) 투자자 섹션을 통해 접근할 수 있으며, 투자자 및 의학 회의의 다른 관리 발표와 함께 제공됩니다. 발표는 사건 발생 후 최소 90일 동안 사이트에서 아카이빙 및 반복 재생이 가능합니다.
Amgen (NASDAQ: AMGN) a annoncé sa participation à la 35e Conférence Annuelle Oppenheimer sur les Sciences de la Vie et de la Santé, prévue pour le mercredi 12 février 2025, à 11h20 ET. Narimon Honarpour, vice-président senior du développement mondial chez Amgen, représentera l'entreprise à la conférence.
La présentation sera accessible via un webinaire en direct, disponible simultanément pour les investisseurs, les médias et le grand public. Le webinaire peut être consulté sur le site d'Amgen (www.amgen.com) dans la section Investisseurs, accompagné d'autres présentations de la direction issues de conférences pour investisseurs et médecins. La présentation restera archivée et accessible en replay sur le site pendant au moins 90 jours après l'événement.
Amgen (NASDAQ: AMGN) hat seine Teilnahme an der 35. jährlichen Oppenheimer-Konferenz für Gesundheits- und Lebenswissenschaften bekannt gegeben, die für Mittwoch, den 12. Februar 2025, um 11:20 Uhr ET geplant ist. Narimon Honarpour, Senior Vice President für globale Entwicklungen bei Amgen, wird das Unternehmen auf der Konferenz vertreten.
Die Präsentation wird über einen Live-Webcast zugänglich sein, der gleichzeitig für Investoren, Medien und die Allgemeinheit verfügbar ist. Der Webcast ist über die Website von Amgen (www.amgen.com) im Bereich Investoren zugänglich, zusammen mit anderen Führungspräsentationen von Investoren- und Medizin-Konferenzen. Die Präsentation wird archiviert und für mindestens 90 Tage nach der Veranstaltung auf der Website verfügbar sein.
- None.
- None.
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube and Threads.
CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors)
View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-the-35th-annual-oppenheimer-healthcare-life-sciences-conference-302371476.html
SOURCE Amgen
FAQ
When is Amgen (AMGN) presenting at the 2025 Oppenheimer Healthcare Conference?
Who will represent AMGN at the 2025 Oppenheimer Healthcare Conference?
How can investors access AMGN's Oppenheimer Conference presentation?
How long will AMGN's 2025 Oppenheimer Conference presentation be available for replay?
